Oncotarget

Exploring the potential therapeutic role of KIAA0930 in cancer cachexia, a new study identifies it as a candidate factor for inducing muscle atrophy in cancer cells, offering hope for developing anti-cachexia therapies

New research paper on assessing p300/CBP in circulating tumor cells. Connection between SIRT2 deacetylation and p300 acetylation in prostate cancer. Use of Exclusion-based Sample Preparation to isolate CTCs. Staining optimization reveals expression of acetyl-p300 and acetyl-H3K18.

Explore a new editorial paper discussing a novel therapeutic approach against melanoma by targeting Hedgehog signaling and BRD4. Learn about the limitations of current SMO inhibitors, the potential of non-canonical HH/GLI signaling, and the researchers' proposal for improving therapeutic response rates.

Exploring a rare case of a 15-year-old boy with Intrathoracic Synovial Sarcoma and BRAF V600E mutation, showcasing the benefits of molecular testing and targeted treatment with a BRAF inhibitor for better patient outcomes

The podcast explores the crucial role of Ras in cancer development, focusing on how inhibitors can target Ras mutations in pancreatic, colorectal, and lung cancers. Advances in engineering Ras binders using protein scaffolds, experimental evolution, and computational techniques are highlighted for more effective treatment. Intracellular protein delivery techniques like fusion with CPPs and nanoparticle coupling offer innovative strategies for precise Ras inhibitor delivery in cells, enhancing targeted cancer treatments.

Exploring the use of cetuximab with radiotherapy for locally advanced cutaneous squamous cell skin cancer, with high response rates and minimal toxicity in a retrospective study of 18 patients.

Experts discuss how preoperative hydroxyprogesterone may improve survival in breast cancer patients by modulating cellular stress response and inflammation. The role of progesterone in overcoming endocrine resistance is highlighted, along with the significance of non-coding RNAs and the SGK1/AP-1/NDRG1 axis in this process.

Researchers discuss the transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors using Nerofe and Doxorubicin. These drugs target KRAS mutations and show promising results in colorectal cancer by downregulating KRAS signaling and enhancing immune response activation.

Researchers discuss the role of ERβ in inflammatory breast cancer, highlighting its significance as a potential tumor suppressor and its implications for treatment outcomes in this rare and aggressive form of breast cancer.

Delve into the dark and bright sides of PLK1 in tumorigenesis as researchers unveil a novel GEM model to study its oncogenic potential. Learn how abnormal PLK1 expression contributes to chromosomal instability and potential therapeutic opportunities for targeted cancer treatments.